Nephro Care India Ltd
₹ 132
-0.90%
10 Jun
12:33 p.m.
About
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes
in the treatment of kidney- related diseases[1]
Key Points
- Market Cap ₹ 217 Cr.
- Current Price ₹ 132
- High / Low ₹ 379 / 122
- Stock P/E 59.7
- Book Value ₹ 32.4
- Dividend Yield 0.00 %
- ROCE 14.4 %
- ROE 10.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from -5.70 days to 75.7 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0.54 | 1.82 | 3.42 | 17.09 | 27.23 | 46.03 | |
| 0.52 | 1.67 | 3.28 | 13.66 | 20.76 | 40.16 | |
| Operating Profit | 0.02 | 0.15 | 0.14 | 3.43 | 6.47 | 5.87 |
| OPM % | 3.70% | 8.24% | 4.09% | 20.07% | 23.76% | 12.75% |
| 0.01 | 0.01 | -0.01 | 0.00 | 0.28 | 1.53 | |
| Interest | 0.04 | 0.03 | 0.02 | 0.07 | 0.09 | 0.11 |
| Depreciation | 0.00 | 0.01 | 0.11 | 0.78 | 0.53 | 2.46 |
| Profit before tax | -0.01 | 0.12 | 0.00 | 2.58 | 6.13 | 4.83 |
| Tax % | 0.00% | 25.00% | 7.75% | 28.06% | 24.64% | |
| -0.01 | 0.09 | -0.01 | 2.37 | 4.41 | 3.64 | |
| EPS in Rs | -10.00 | 90.00 | -0.20 | 47.40 | 3.71 | 2.21 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 143% |
| 3 Years: | 138% |
| TTM: | 69% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 226% |
| 3 Years: | 123% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 23% |
| Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.50 | 0.50 | 11.90 | 16.49 |
| Reserves | 0.07 | 0.01 | 0.00 | 2.03 | 3.12 | 37.00 |
| 0.40 | 0.69 | 2.54 | 2.48 | 0.00 | 0.00 | |
| 0.30 | 0.42 | 1.60 | 3.25 | 5.94 | 14.79 | |
| Total Liabilities | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 |
| 0.45 | 0.06 | 1.39 | 3.01 | 4.74 | 31.50 | |
| CWIP | 0.00 | 0.45 | 1.90 | 0.00 | 0.86 | 0.59 |
| Investments | 0.24 | 0.00 | 0.00 | 2.00 | 6.51 | 18.58 |
| 0.09 | 0.62 | 1.35 | 3.25 | 8.85 | 17.61 | |
| Total Assets | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0.23 | 0.62 | 4.12 | 0.91 | 6.96 | ||
| -0.06 | -2.81 | -2.33 | -7.54 | -39.56 | ||
| 0.28 | 2.32 | -0.08 | 5.60 | 35.96 | ||
| Net Cash Flow | 0.44 | 0.13 | 1.71 | -1.03 | 3.37 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 20.28 | 0.85 | 2.01 | 25.61 |
| Inventory Days | 8.83 | 41.93 | 35.25 | 14.07 | 34.38 | |
| Days Payable | 94.19 | 113.45 | 69.03 | 75.17 | 107.32 | |
| Cash Conversion Cycle | 0.00 | -85.36 | -51.24 | -32.93 | -59.09 | -47.33 |
| Working Capital Days | -168.98 | -74.20 | -117.40 | -55.96 | -36.86 | 75.73 |
| ROCE % | 25.21% | 1.60% | 65.84% | 60.41% | 14.42% |
Documents
Announcements
-
Updates
5 June 2025 - No deviation in IPO fund utilization for half year ended March 31, 2025, certified by auditors.
-
Press Release
29 May 2025 - Nephro Care reports 90.10% PAT rise in H2FY25; plans 22 clinics by March 2026; developing low-cost AI dialysis machine.
-
Statement of deviation(s) or variation(s) under Reg. 32
29 May 2025 - No deviation in IPO fund utilization for half year ended March 31, 2025, certified by auditors.
-
Related Party Transactions
28 May 2025 - Disclosure of related party transactions worth ₹194.65 lakh for half year ended March 31, 2025.
-
Outcome of Board Meeting
28 May 2025 - Approved FY25 audited results; authorized Bandra project execution; formed Business Alliance & Growth Committee.
Business Overview:[1][2]
NCIL provides comprehensive medical services for renal patients as a one-stop treatment center in Kolkata. It offers clinical and lifestyle solutions for renal insufficiency, covering lifestyle, physiological, and spiritual wellness. The company specializes in non-invasive services.